Regions of hypoxia are a common feature of solid tumours. When tumour cells are exposed to hypoxic stress, transcription of a battery of genes is initiated. The angiogenic factor adrenomedullin (ADM) is a hypoxia regulated gene. ADM is thought to act through the G protein-coupled receptor calcitonin receptor-like receptor (CRLR), with speci®city being conferred by the receptor associated modifying protein 2 (RAMP2). Here we report for the ®rst time that ADM treated or stably transfected Ishikawa cells overexpressing ADM show increased resistance to hypoxia induced apoptosis. These cells also show an upregulation of the oncoprotein Bcl-2, which is protective against hypoxic cell death when transiently transfected into Ishikawa cells. Since Ishikawa cells express the putative ADM-receptor CRLR ± RAMP2 the production and secretion of ADM with the consecutive upregulation of Bcl-2 could establish an autocrine/ paracrine mechanism rescuing malignant cells from hypoxic cell death. These results, taken together with our previous ®ndings that ADM is an angiogenic factor which is upregulated by the nonsteroidal antiestrogen tamoxifen (TAM) in endometrial cells, implicate this peptide as a promoter of tumour growth and a possible target for anticancer strategies. Oncogene (2001) 20, 2937 ± 2945.
Introduction
Adrenomedullin (ADM) is a 52-amino-acid peptide which belongs to the calcitonin gene-related peptide family (Wimalawansa, 1997) . ADM has been shown to act through the G protein-coupled receptor calcitonin receptor-like receptor (CRLR), with a speci®city for ADM being conferred by the receptor associated modifying protein 2 (RAMP2) (Kamitani et al., 1999; McLatchie et al., 1998) . ADM, initially isolated from a human phaeochromocytoma, is expressed in a variety of benign and malignant tissues and human cancer cell lines (Hinson et al., 2000) .
ADM is a pluripotent peptide with properties ranging from inducing vasorelaxation to acting as a growth factor for various benign and malignant cell types (Hinson et al., 2000) . We were the ®rst to show that ADM is an angiogenic factor (Zhao et al., 1998) . Furthermore we demonstrated that ADM expression in uterine leiomyomas (benign smooth muscle tumours) correlated with vascular density (Hague et al., 2000) . In addition, we reported the presence of ADM in human endometrium where it was upregulated by the nonsteroidal antiestrogen tamoxifen (TAM) (Zhao et al., 1998) . TAM, the long term endocrine treatment of choice for selected patients with breast cancer, is known to induce proliferative changes of the endometrium, increasing the risk of developing endometrial cancer (Bergman et al., 2000; Carthew et al., 2000) . Recent evidence of a role for ADM in vascular development has come from the ADM knockout mouse that shows extreme hydrops fetalis and cardiovascular abnormalities (Caron and Smithies, 2001) .
Recently, ADM has been reported to be upregulated by hypoxia (Cormier-Regard et al., 1998; Nakayama et al., 1998) . Expression was shown to be under hypoxiainducible transcription factor-1 (HIF-1) regulation similar to that of classic oxygen-regulated genes such as erythropoietin (Epo) or vascular endothelial growth factor (VEGF) (Garayoa et al., 2000; Nguyen and Claycomb, 1999) . However, the function of ADM in hypoxic cells is currently unknown.
Regions of hypoxia are a common feature of solid tumours. Uncontrolled malignant growth leads to limited vascular supply and consequently to hypoxia at distances beyond the diusion capacity of oxygen (100 ± 150 mm) (Thomlinson and Gray, 1955) . It is thought that hypoxia functions as a selective pressure for solid tumours leading to progression to a more malignant phenotype by selection for an apoptosisresistant cell population . Apoptosis (also called programmed cell death) is a genetically controlled, morphologically unique process, which plays a central role in regulating tissue homeostasis by eliminating cells that are harmful or no longer required. Dysregulation of apoptosis results in abnormal cell growth and death, and can promote tumour expansion (Naik et al., 1996) . Bcl-2 is the prototype of a class of oncogenes which is involved in the regulation of apoptosis (Adams and Cory, 1998; Pellegrini and Strasser, 1999) . Bcl-2 acts as an antiapoptotic factor which suppresses programmed cell death triggered by stimuli such as hypoxia (Shimizu et al., 1995) .
We have studied the role of ADM in endometrial carcinoma cells under hypoxia. Our data indicate for the ®rst time that ADM confers resistance to hypoxic cell death in an autocrine/paracrine manner. This antiapoptotic action appears to be mediated by upregulation of the Bcl-2 oncoprotein. These results, taken together with our previous ®ndings that ADM is an angiogenic factor which is upregulated by tamoxifen, implicates ADM as a promoter of tumour growth in human endometrium.
Results

ADM mRNA and peptide expression is increased under hypoxia
RNAse protection assay showed a time dependent upregulation of ADM mRNA expression under hypoxia. ADM mRNA expression levels after 18 h of hypoxia were about 15-fold higher compared with the normoxic controls ( Figure 1a ). This result could also be mimicked with cobalt chloride (500 mM), which induced a 10-fold increased expression of ADM mRNA after an incubation period of 8 h (data not shown).
We conducted further experiments to address the question of whether the induction of ADM mRNA under hypoxic conditions is accompanied by an increase of peptide expression. Since ADM is known to be a peptide which is rapidly secreted from malignant cells, concentrations in the conditioned media of Ishikawa cells under normoxia and hypoxia were evaluated (Miller et al., 1996) . Values of accumulated IR-ADM in cultured media of cells under 0.1% O 2 were signi®cantly higher than those from normoxic cells after 24 h (P50.05) (Figure 1b) .
Ishikawa-cells express the CRLR and RAMP2
We asked whether Ishikawa cells could be capable of responding to the secreted ADM under hypoxia. RT ± PCR was used to evaluate the expression of the putative ADM-receptor CRLR ± RAMP2. Ishikawa cells both expressed CRLR and RAMP2 (Figure 2 ). This result points to a possible autocrine and/or paracrine mechanism of action of ADM.
Addition of ADM increases hypoxic cell survival
In the hypoxia experiments addition of ADM dose dependently (10 712 ± 10 76 M) inhibited hypoxia induced cell death in Ishikawa cells. About 40% less hypoxic cell death (sub-G1 peak) was observed after 36 h of hypoxia at a concentration of 10 76 M ADM (P50.05) ( Figure 3 ).
To distinguish apoptotic from necrotic cells, double staining for exposed phosphatidylserine (Annexin-V) and propidium iodide (PI) exclusion was performed using un®xed cells. Stably transfected ADM-overexpressing Ishikawa cells are more resistant to hypoxic cell death To further evaluate the ability of ADM to protect Ishikawa cells from hypoxic cell death, stable transfectants were created. Two Ishikawa cell clones (Ishi-ADM1 and Ishi-ADM2) highly expressing ADM mRNA and peptide were identi®ed by RT ± PCR, immunohistochemistry and FACS analysis ( Figure 5 ). Those clones were examined for thir resistance to hypoxic cell death. After exposure to hypoxia the sub-G1 populations of both ADM high-expressing cell clones were up to 30% lower than those of control clones (P50.05) (data not shown). Staining for Annexin-V also revealed a signi®cant increased survival of transfected cells vs controls (P50.05) ( Figure 6 ).
ADM increases Bcl-2 expression
In order to elucidate the mechanism underlying the suppressive eect of ADM on hypoxic cell death we examined whether ADM might alter the expression of the anti-apoptotic factor Bcl-2.
RT ± PCR analysis was used to examine the eect of ADM on the expression of Bcl-2 under normoxia and hypoxia. When added to cultures of Ishikawa cells ADM induced a sixfold increase (measured by relative band density) in the level of Bcl-2 mRNA after 6 h of incubation under hypoxia or normoxia ( Figure 7a ). To con®rm these results, Western blots were used to visualise the induction of Bcl-2 peptide by ADM. A dose dependent up to ®vefold increase of Bcl-2 peptide expression could be observed after hypoxic treatment of Ishikawa cells with ADM at concentrations of 10 712 ± 10 76 M for 8 h (Figure 7b ). Ishikawa cells stably transfected with ADM overexpress Bcl-2
After having shown Bcl-2 expression to be upregulated by external application of ADM we expected the Bcl-2 expression in Ishikawa cell-clones stably transfected with ADM to be increased. Indeed, the cell clones overexpressing ADM and exhibiting increased resistance to cell death in the hypoxia experiments both overexpressed Bcl-2 up to sixfold in comparison to the controls (Figure 8 ). These results further con®rmed the mechanism of Bcl-2 induction by ADM in Ishikawa cells.
Bcl-2 increases survival in transiently transfected Ishikawa-cells
We ®nally asked whether Bcl-2 has the ability to protect Ishikawa-cells from hypoxic cell death. Therefore Ishikawa cells were transiently transfected with an expression plasmid for Bcl-2. Seventy-two hours after transfection the cells were exposed to hypoxia. Bcl-2 transfected cells showed 25% less death (sub-G1 peak) than controls in¯ow cytometric evaluation (P50.05) (Figure 9 ). This observation veri®es the role of Bcl-2 as a suppressor of hypoxic cell death in Ishikawa cells.
Discussion
Our initial experiments with the endometrial carcinoma cell line Ishikawa clearly demonstrated that ADM belongs to the family of genes which are upregulated under hypoxic stress. We could also show that not only gene transcription but also ADM peptide secretion is increased under hypoxia. In addition, ADM upregulation was mimicked by CoCl 2 which is known to change the redox state of the central iron atom of heme proteins similarly to the eect of hypoxia (Gleadle et al., 1995) . These results con®rm the observations in several animal and cell systems that ADM seems to be a ubiquitously hypoxiaregulated gene (Garayoa et al., 2000; Hofbauer et al., 2000) . Hypoxic regulation of ADM is known to be controlled by a common oxygen sensing pathway in which they key player is the HIF-1 transcription factor. HIF-1 is a heterodimer composed of HIF-1a and HIF-1b/ARNT subunits, both representing members of the PAS (Per, ARNT, Sim) basic ± helix ± loop helix family (Blancher and Harris, 1998) . HIF-1 binds to hypoxia response elements (HREs) several of which have been described in the promoter of ADM (Garayoa et al., 2000) . Thus ADM belongs to a diverse family of HIF-1-regulated genes, including VEGF, Epo, insulin-like growth factor binding protein 1 (IGFBP-1) and the platelet-derived endothelial cell growth factor/thymidine phosphorylase (PD-ECGF/ TP) which are all known to be highly expressed in malignant tumours.
It is thought that hypoxia functions as a selective pressure for solid tumours, leading to the progression to a more malignant phenotype by selecting for an apoptosis-resistant population of cells which show a distinct expression of hypoxia controlled genes . As those cells are more resistant to conventional radio-and chemotherapy and show high metastatic potential they signi®cantly impact on clinical response to anticancer therapies and prognosis (Hockel et al., 1999; McGill, 1997) . However, it is uncertain which hypoxia regulated genes are involved in the development of an increased malignant phenotype and even less is known about their function. Our experiments with Ishikawa cells show for the ®rst time that ADM protects malignant cells from hypoxia-induced cell death. Together with our observation that Ishikawa cells express the putative ADM-receptor CRLR ± RAMP2, the production and secretion of ADM in hypoxic areas of tumours could establish an autocrine/paracrine-mediated mechanism rescuing malignant cells from apoptosis. Since ADM has additional angiogenic and vasodilator capacities (Hinson et al., 2000; Zhao et al., 1998) , it may also induce vascular growth and promote tumour nutrition.
Although our study is the ®rst to describe the antiapoptotic eect of ADM under hypoxia, prior observations have shown ADM to antagonize serum deprivation-induced apoptosis in endothelial cells (Kato et al., 1997) . Interestingly, in glomerular mesangial cells ADM was shown to evoke a contrary eect by increasing apoptosis during serum starvation (Parameswaran et al., 1999) . These results suggest a cell type dependent eect of ADM on apoptosis, as has been demonstrated for its mitogenic eects (Hinson et al., 2000) .
We found ADM upregulated the oncoprotein Bcl-2 at the mRNA and peptide level in Ishikawa cells under normoxia and hypoxia. Bcl-2 is a well known protective factor against many apoptotic stimuli, including hypoxia (Shimizu et al., 1996) . It is thought to block apoptosis by retaining Cytochrome c in the mitochondria, thereby inhibiting caspase-3 activation and subsequent downstream apoptotic events (Yang, 1997) . In con®rmation, Bcl-2 transfected Ishikawa-cells showed a decreased hypoxic apoptotic rate in our experiments, an eect which has been described before for other cell types such as hepatoma or endothelium (NoÈ r et al., 1999; Yamabe et al., 1998) .
High Bcl-2-protein levels or aberrant Bcl-2-gene expression have been reported in a wide variety of solid tumours, including endometrial cancer, and it was suggested that disruption of apoptosis as a result of changes of Bcl-2 levels is an important regulatory step in malignant growth and/or acquisition of more aggressive neoplastic phenotypes (Ricca and Biroccio, 2000) . This might explain why Bcl-2 expression is associated with poor prognosis in several types of malignancies (Sakuragi et al., 1998) . Our study is the ®rst to report the anti-apoptotic mechanism of Bcl-2 upregulation by ADM. Others have recently demonstrated other pathways: ADM antagonizes serum-deprivation-induced endothelial apoptosis by upregulation of the transcription factor Max, the heterodimeric partner of c-Myc (Shichiri et al., 1999) . The proto-oncogene c-Myc transcriptionally controls the expression of a diverse group of genes and its deregulation leads to a cellular imbalance in the expression of genes that promote proliferation, transformation and apoptosis. For its function as transcriptional activator c-Myc is believed to require dimerization with Max. It was anticipated that the presence of abundant Max ± e.g. upregulated by ADM ± leads to the formation of Max ± Max homodimers which suppress apoptosis by antagonizing the eect of the Myc ± Max-transcription complex through competition for recognition sites (Shichiri et al., 1999) .
Interactions have also been shown between Bcl-2 and Myc. Numerous studies on c-Myc function have shown that c-Myc changes the balance between proliferation and apoptosis in the direction of programmed cell death under conditions of hypoxia or serum depletion (Cory et al., 1999) . However, in vivo experiments, including bitransgenic mice models, have shown that in Bcl-2 overexpressing tumours the c-Myc induced proapoptotic impulse is counteracted enabling cellular proliferation (Jager et al., 1997; Pellegrini and Strasser, 1999) . The exact mechanism by which Bcl-2 interacts with c-Myc is uncertain. It is believed to inhibit apoptosis downstream of c-Myc since it does not appear to aect c-Myc mediated p53 protein accumulation (Alarcon et al., 1996) .
It is noteworthy that the products of both antiapoptotic ADM target genes, Bcl-2 and Max, interact with Myc. However whether Bcl-2 and Max are part of a common mechanism inhibiting Myc-triggered cell death remains to be determined. ADM expression is upregulated by TAM in human endometrium (Elkas et al., 2000; Zhao et al., 1998) . TAM is used for the treatment of breast cancer and is being evaluated as a prevention agent in women at high risk of developing the disease (Cuzick, 2000) . A major concern is the proliferative eect of TAM on the endometrium, which is associated with a 2 ± 7-fold increased risk of endometrial cancer for long-term tamoxifen users (Barakat, 1996; Bergman et al., 2000; Carthew et al., 2000) . The mitogenic and antiapoptotic properties of ADM point to this peptide being a mediator of tamoxifen's adverse endometrial eects. The mechanism by which TAM stimulates the ADM gene is uncertain since it lacks palindromic oestrogen response elements (Ishimitsu et al., 1994) . The observation that TAM induces hypoxia in xenografts combined with our ®ndings indicate an indirect hypoxia-mediated pathway (Evans et al., 1997; Furman et al., 1992) .
In conclusion, the present study demonstrates that ADM antagonizes hypoxia induced cell death of endometrial cancer cells by up-regulation of Bcl-2 in an autocrine/paracrine manner. These observations, taken together with our previous results that ADM is an angiogenic factor, implicates ADM as a promoter of tumour growth and a possible target for anticancer strategies.
Materials and methods
Materials and cells
The human ADM cDNA was a gift from Dr Kitamura, First Department of Internal Medicine, Kihara, Japan (Kitamura et al., 1993) . The expression plasmid hBcl-2/pcBABE was provided by Dr Norbury, Cell Cycle Group, Institute of Molecular Medicine, Oxford, UK. Human ADM-(1-52) was synthesized by the ICRF-Peptide-Unit (Clare Hall, London, UK). All reagents were purchased from Sigma (Poole, UK), unless stated otherwise. The steroid receptor positive endometrial carcinoma cell line Ishikawa was provided from the Clare Hall Laboratories (Imperial Cancer Research Fund, London, UK). Cells were routinely cultured at 378C and 5% CO 2 in DMEM supplemented with 10% FCS and 4 mM glutamine.
Hypoxia and cobalt chloride treatment
Hypoxic incubations were performed in an oxygen-regulator incubator (Forma Scienti®c, Labtech, UK) at 0.1% O 2 which re¯ects the oxygen tension in solid tumours (Vaupel, 1993) . Cells were grown in DMEM/1% FCS for 24 h before incubation at 0.1% O 2 in DMEM/1% FCS.
Ishikawa cells were treated with 500 mM cobalt chloride for 8 h to mimic hypoxia.
Vector construction and stable transfection of Ishikawa cells
The full-length cDNA for human ADM was cloned into pcDNAl/Neo to give plasmid pCMV ± ADMneo in which expression of ADM is constitutively driven by the CMVpromoter. Ishikawa cells were transfected with pCMV ± ADMneo or pcDNAl/Neo (empty vector control) by electroporation. Transfected cells were selected for neomycin resistance by treating them with the antibiotic G418 (500 mg/ ml) in DMEM/10% FCS for 12 weeks. Isolated clones were characterized for their ADM-mRNA and peptide expression by RT ± PCR, immunohistochemistry and FACS analysis.
Transient transfection assays
The full-length cDNA for human Bcl-2 cloned into the expression plasmid pcBABE and the empty vector were transfected into Ishikawa cells using Fugene reagent (Roche, Lewes, UK). Transfection eciency was evaluated by cotransfection with green¯uorescent protein (Invitrogen, Groningen, The Netherlands). Seventy-two hours after transient transfection Ishikawa cells were exposed to hypoxia.
Oncogene Adrenomedullin in tumourogenesis MK Oehler et al.
RNA isolation
Total RNA (derived from 2610 7 cells) for RNAse protection and RT ± PCR experiments was extracted using TRl-reagent (Sigma) according to the manufacturer's instructions. All samples were stored at 7708C until assay.
Synthesis of riboprobes
A 261 bp fragment of the hADM cDNA was subcloned into Bluescript Vector and transcribed with T7 RNA polymerase to create 32 P-CTP labelled antisense riboprobes. ADM riboprobes were prepared to the highest speci®c activity possible. As loading control U6 small nuclear RNA (GeneBank accession no X01366) was used. To account for the signal strength of the highly abundant control a riboprobe of signi®cantly lower speci®city was prepared.
RNAse protection assay
RNAse protection assays followed previously described methods (Petersen et al., 1995) . Brie¯y, 10 mg total RNA were denatured and hybridized with 32 P-CTP labelled riboprobes. Single-stranded RNA was digested with RNase H (Promega, Southampton, UK) and the protected fragments size-fractionated on a 6% polyacrylamide gel. The signal intensity was quanti®ed on a phosphoimager (Molecular Dynamics, Sunnyvale, USA).
Immunoblot analysis
Pepide isolation For isolation of ADM peptide out of cell culture supernatant, serum-free DMEM was conditioned by con¯uent cultures for 48 h. The medium was concentrated (1006) with a Centricon-3-Concentrator followed by a Microcon-5-Concentrator (Amicon, Beverley, USA). Protein concentrations were quanti®ed using the BCA protein assay (Pierce, Rockford, USA). The samples were stored at 7808C until assay.
Immunoblotting For immunoblotting samples were run on a 10% SDS gel for Bcl-2 or on a gradient 10 ± 20% tricine, SDS ± PAGE (BioRad, Hercules, USA) for ADM detection. The proteins were electrophoretically transferred onto a polyvinylidene di¯uoride membrane (Immobilon PVDF ± Millipore, Watford, UK). The PVDF membrane was blocked for 2 h in PBS with 0.1% Tween-20, 5% bovine serum albumin and incubated in a 1 : 1000 dilution of a monoclonal mouse anti-human Bcl-2 antibody (DAKO, Glostrup, Denmark) or a polyclonal rabbit anti-human ADM antibody (Peninsula Laboratories, Merseyside, UK). Binding was visualized by a horseradish peroxidase-conjugated rabbit anti-mouse IgG or pig anti-rabbit IgG, respectively and developed with ECL Western blotting reagents (Amersham, Little Chalfont, UK). Quanti®cation of protein expression was performed by densitometry (Fluorchem, Alpha Innotech Corp, USA).
Radioimmunoassay
Peptides in the culture medium were extracted according to a previously published method using Sep-Pak C18 cartridges (Waters, Milford, USA) (Kato et al., 1997) . Human ADM (1-52) was quanti®ed by a competitive RIA (Peninsula Laboratories, Merseyside, UK) using rabbit-antiserum. Samples or standards were preincubated with antiserum prior to addition of tracer. Bound peptide was separated with goat anti-rabbit IgG. Assay detection limit was 1 pmol/l.
Cell death analysis
The cellular DNA content was evaluated as described by Ongkeko et al. (1995) with slight modi®cations. Cells were harvested and ®xed in cold 60% ethanol for 1 h at 7208C and then suspended in phosphate buered saline containing 0.1% Triton X-100. After the addition of propidium iodide (PI, 40 mg/ml) and RNAse A (100 mg/ml) the cell suspension was incubated for 1 h at 48C in the dark and ®nally analysed using a FACScan (Becton Dickinson, Franklin Lakes, USA). The proportion of cells undergoing cell death in each population was estimated by quanti®cation of cells with a DNA content less than that of normoxic cells in G1 (sub-G1 peak).
To further distinguish apoptotic from necrotic cells double staining for exposed phosphatidylserine and PI exclusion was performed as follows: Cells were harvested, washed twice with PBS and resuspended in binding buer (10 mM HEPES/ NaOH, pH 7.4, 140 mM NaCl, 2.5 mM CaCl 2 ). Five ml Annexin V-FlITC antibody (Pharmingen, San Diego, USA) and 10 ml PI (50 mg/ml) were added to the cells. After incubation for 15 min at room temperature in the dark the cells were analysed by a FACScan. The following controls were used to set up compensation and quadrants: (a) unstained cells; (b) cells stained with Annexin V-FITC (no PI) and cells stained with PI (no Annexin V-FITC).
Statistical analysis
Statistics were performed using the SPSS software package. Comparisons between groups were made applying the Wilcoxon matched pairs test.
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